Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 22 January 2019, 16:54 HKT/SGT
Share:
    

Source: Eisai
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time
Highest Ranked Japanese Company

TOKYO, Jan 22, 2019 - (JCN Newswire) - Eisai Co., Ltd. has been listed in the 2019 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's fourth inclusion on the list. Ranked 73rd, Eisai was the highest ranking Japanese company among the eight Japanese companies listed in the Global 100.

The Global 100 evaluates the sustainability of approximately 7,500 of the world's major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance). Since 2005, those companies ranking among the top 100 in the world have been announced each year at the World Economic Forum in Davos. The Global 100 is based on up to 21 key performance indicators covering financial management, clean revenue, supplier performance, employee management and resource management, with the evaluations carried out based on data publicly disclosed in financial filings, integrated reports, or through other such channels.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this corporate philosophy, Eisai is striving to sustainably enhance corporate value by strengthening its ESG initiatives and increasing non-financial value.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Jan 22, 2019 16:54 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 24, 2019 08:36 HKT/SGT
Eisai Selected as Competitive ICT Strategy Company for 2019
Apr 8, 2019 13:06 HKT/SGT
Eisai: Japan MHLW Grants Sakigake Designation to Novel Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor E7090
Apr 8, 2019 10:43 HKT/SGT
Eisai to Launch Chocola BB Sparkling Kiwi & Lemon Flavor
Apr 5, 2019 09:45 HKT/SGT
Eisai to Launch "Travelmin Support" as Series' First Quasi-Drug
Mar 29, 2019 10:46 HKT/SGT
Eisai: Data Safety Monitoring Board Recommends Continuation of Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease
Mar 22, 2019 10:37 HKT/SGT
Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease
Mar 22, 2019 10:23 HKT/SGT
Eisai to Present Latest Research on Alzheimer's Disease / Dementia Pipeline at the 14th International Conference on Alzheimer's & Parkinson's Diseases
Mar 21, 2019 23:25 HKT/SGT
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease
Mar 12, 2019 07:43 HKT/SGT
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
Mar 7, 2019 11:30 HKT/SGT
Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: